US5525606A
(en)
|
1994-08-01 |
1996-06-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
|
DE19512484A1
(de)
|
1995-04-04 |
1996-10-17 |
Bayer Ag |
Kohlenhydratmodifizierte Cytostatika
|
ES2257756T3
(es)
*
|
1996-03-12 |
2006-08-01 |
Sanofi-Aventis Deutschland Gmbh |
Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
|
ATE365562T1
(de)
*
|
1996-05-03 |
2007-07-15 |
Immunomedics Inc |
Zielgerichtete kombinations-immuntherapie für krebs
|
DE19631288A1
(de)
*
|
1996-08-02 |
1998-02-05 |
Hoechst Ag |
Neue Inhibitoren der ß-Glucuronidase
|
JP2001501601A
(ja)
*
|
1996-09-12 |
2001-02-06 |
メルク エンド カンパニー インコーポレーテッド |
前立腺ガンの治療において有用な共役体
|
DE19720312A1
(de)
*
|
1997-05-15 |
1998-11-19 |
Hoechst Ag |
Zubereitung mit erhöhter in vivo Verträglichkeit
|
US6127333A
(en)
*
|
1997-07-10 |
2000-10-03 |
Merck & Co., Inc. |
Conjugates useful in the treatment of prostate cancer
|
US6391305B1
(en)
|
1997-09-10 |
2002-05-21 |
Merck & Co., Inc. |
Conjugates useful in the treatment of prostate cancer
|
ZA9810974B
(en)
*
|
1997-12-02 |
1999-06-03 |
Merck & Co Inc |
Conjugates useful in the treatment of prostate cancer
|
US20040081659A1
(en)
*
|
1997-12-02 |
2004-04-29 |
Merck & Co., Inc. |
Conjugates useful in the treatment of prostate cancer
|
NZ504615A
(en)
*
|
1997-12-02 |
2003-05-30 |
Merck & Co Inc |
Conjugates useful in the treatment of prostate cancer
|
CA2319836C
(en)
|
1998-02-06 |
2010-11-23 |
De Montfort University |
Hydroxylation activated prodrugs
|
GB2334256A
(en)
|
1998-02-12 |
1999-08-18 |
Univ Montfort |
Hydroxylation activated prodrugs
|
AU2531599A
(en)
*
|
1998-02-12 |
1999-08-30 |
De Montfort University |
Hydroxylation activated drug release
|
US6043367A
(en)
*
|
1998-09-30 |
2000-03-28 |
Roffler; Steve |
Proactive antitumor compounds
|
US6174858B1
(en)
|
1998-11-17 |
2001-01-16 |
Merck & Co., Inc. |
Conjugates useful in the treatment of prostate cancer
|
AU772153B2
(en)
*
|
1999-02-12 |
2004-04-08 |
Molecular Insight Pharmaceuticals, Inc. |
Matrices for drug delivery and methods for making and using the same
|
FR2791679B1
(fr)
*
|
1999-03-31 |
2003-04-11 |
Fabre Pierre Dermo Cosmetique |
Bioprecurseurs aptes a liberer un derive retinoique par mise a profit de l'activite enzymatique de la surface cutanee et compositions pharmaceutiques et/ou cosmetiques
|
US6703020B1
(en)
*
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
DE19925810A1
(de)
*
|
1999-06-07 |
2000-12-14 |
Paz Arzneimittelentwicklung |
Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung
|
US6734192B1
(en)
|
1999-08-23 |
2004-05-11 |
Mp-1 Inc. |
Treatment of viral infections
|
GB2355007A
(en)
*
|
1999-10-08 |
2001-04-11 |
Michael Francis Holick |
Tamoxifen analogue glycosides and use thereof
|
WO2002032400A1
(en)
*
|
2000-10-16 |
2002-04-25 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
AU2003230750A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Threshold Pharmaceuticals, Inc. |
Compositions and methods for treating cancer
|
CA2490626A1
(en)
*
|
2002-06-20 |
2003-12-31 |
Nippon Suisan Kaisha, Ltd. |
Prodrug, medicinal utilization thereof and process for producing the same
|
EP1537146B9
(de)
|
2002-07-15 |
2011-07-06 |
Board Of Regents, The University Of Texas System |
Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
|
WO2004043396A2
(en)
*
|
2002-11-09 |
2004-05-27 |
Nobex Corporation |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
CA2506080A1
(en)
|
2002-11-14 |
2004-05-27 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
DE10256982A1
(de)
|
2002-12-05 |
2004-06-24 |
Schering Ag |
Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
|
EP1581218A1
(de)
*
|
2002-12-05 |
2005-10-05 |
Schering AG |
Epothilone derivate für ortspezifische verabreichung in der behandlung von proliferativen krankheiten
|
AU2005216251B2
(en)
*
|
2004-02-23 |
2011-03-10 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
EA016186B1
(ru)
*
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
EP1881000A1
(de)
*
|
2006-07-17 |
2008-01-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Konjugate der 2-Fluoro-2-deoxyglucose und deren Verwendung als Antitumormittel
|
US8232254B2
(en)
|
2006-10-06 |
2012-07-31 |
Wisconsin Alumni Research Foundation |
Colchicine neoglycosides and methods for their synthesis and use
|
CA2672468A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
WO2008153394A2
(en)
*
|
2007-06-14 |
2008-12-18 |
Academisch Medisch Centrum |
Novel anti-inflammatory pro-drugs
|
FR2920877B1
(fr)
*
|
2007-09-10 |
2010-01-22 |
Commissariat Energie Atomique |
Substrats fluorescents saccharidiques, leur procede de procede de preparation et leurs utisations.
|
NZ586053A
(en)
|
2007-11-09 |
2012-09-28 |
Peregrine Pharmaceuticals Inc |
Anti-vegf antibody compositions and methods
|
CA2716390C
(en)
|
2008-02-25 |
2016-08-23 |
Eyegate Pharma S.A.S. |
Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
|
CA2793890C
(en)
|
2010-04-15 |
2017-08-15 |
Spirogen Developments Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
FR2960153B1
(fr)
|
2010-05-20 |
2012-08-17 |
Centre Nat Rech Scient |
Nouveaux bras autoreactifs et prodrogues les comprenant
|
EP3812387A1
(de)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclische proteinkinase-hemmer
|
EP2750713B1
(de)
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine und konjugate daraus
|
CN104080811B
(zh)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
EP2906297B1
(de)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-antikörper-konjugate
|
ES2703151T3
(es)
|
2012-10-12 |
2019-03-07 |
Adc Therapeutics Sa |
Conjugados de anticuerpos de pirrolobenzodiazepinas
|
EP2906253B9
(de)
|
2012-10-12 |
2019-04-10 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
CN105102004B
(zh)
|
2012-10-12 |
2019-01-25 |
Adc疗法责任有限公司 |
吡咯并苯并二氮杂卓-抗cd22抗体结合物
|
ME03486B
(de)
|
2012-10-12 |
2020-01-20 |
Medimmune Ltd |
Pyrrolobenzodiazepine und Konjugate davon
|
PT2906296T
(pt)
|
2012-10-12 |
2018-06-01 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpo
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
BR112015014669B1
(pt)
|
2012-12-21 |
2023-09-26 |
Medimmune Limited |
Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
EP2958907B1
(de)
|
2013-02-19 |
2018-02-28 |
Novartis AG |
Benzothiophenderivate und zusammensetzungen damit als selektive östrogenrezeptorabbauer
|
EP2968596B1
(de)
|
2013-03-13 |
2019-03-06 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate davon
|
US20160031887A1
(en)
|
2013-03-13 |
2016-02-04 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
BR112015021965B1
(pt)
|
2013-03-13 |
2022-05-03 |
Medimmune Limited |
Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054983B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
EP3054986B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
EP3125943A4
(de)
|
2014-04-04 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Phosphatbasierte linker für intrazelluläre verabreichung von arzneimittelkonjugaten
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
EP3193940A1
(de)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate daraus
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
BR112017011111A2
(pt)
|
2014-11-25 |
2017-12-26 |
Adc Therapeutics Sa |
conjugados de pirrolobenzodiazepina-anticorpo
|
PE20171307A1
(es)
|
2014-12-23 |
2017-09-05 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos
|
US10189813B2
(en)
|
2015-03-25 |
2019-01-29 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
JP6718889B2
(ja)
|
2015-06-19 |
2020-07-08 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
EP3310779B1
(de)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Verbindungen und zusammensetzungen zur hemmung der aktivität von shp2
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3359194A4
(de)
|
2015-10-06 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Antikörper-wirkstoff- konjugat für entzündungshemmende anwendungen
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
US10869929B2
(en)
|
2016-01-29 |
2020-12-22 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017149463A1
(en)
|
2016-03-01 |
2017-09-08 |
Novartis Ag |
Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
SI3452465T1
(sl)
|
2016-05-04 |
2021-04-30 |
Genoscience Pharma |
Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
|
PL3468972T3
(pl)
|
2016-06-14 |
2020-11-16 |
Novartis Ag |
Związki i kompozycje do hamowania aktywności shp2
|
JP2019524872A
(ja)
|
2016-06-20 |
2019-09-05 |
ノバルティス アーゲー |
癌の治療に有用なイミダゾピリミジン化合物
|
JP2019522049A
(ja)
|
2016-06-20 |
2019-08-08 |
ノバルティス アーゲー |
トリアゾロピリジン化合物及びその使用
|
EP3472168B1
(de)
|
2016-06-20 |
2024-01-10 |
Novartis AG |
Kristalline formen einer triazolopyrimidinverbindung
|
WO2018005963A1
(en)
*
|
2016-07-01 |
2018-01-04 |
Zoneone Pharma, Inc. |
Synthesis of new methylumbelliferone prodrugs and their incorporation into lipid-based drug delivery formulations
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
UA125198C2
(uk)
|
2017-02-08 |
2022-01-26 |
Ейдісі Терапьютікс Са |
Кон'югати піролобензодіазепін-антитіло
|
WO2018146506A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Universitat Politècnica De València |
Therapeutic derivatives
|
ES2926144T3
(es)
|
2017-04-18 |
2022-10-24 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
JP7408396B2
(ja)
|
2017-04-20 |
2024-01-05 |
アーデーセー セラピューティクス ソシエテ アノニム |
併用療法
|
WO2018229222A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
UY37774A
(es)
|
2017-06-19 |
2019-01-31 |
Novartis Ag |
Compuestos 5-cianoindol sustituidos y usos de los mismos
|
HRP20220311T1
(hr)
|
2017-08-18 |
2022-05-13 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
TW201912639A
(zh)
|
2017-09-11 |
2019-04-01 |
美商克魯松藥物公司 |
Shp2之八氫環戊烷并[c]吡咯別構抑制劑
|
CN108021787B
(zh)
*
|
2017-12-08 |
2021-10-15 |
华东理工大学 |
一种根据基元反应拓扑结构构建动态代谢网络的方法
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
KR20240033296A
(ko)
|
2018-07-25 |
2024-03-12 |
어드밴스드 엑셀러레이터 어플리케이션즈 |
안정한 농축 방사성 핵종 복합체 용액
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
US20200115389A1
(en)
|
2018-09-18 |
2020-04-16 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
JP2022502496A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス,インコーポレイティド |
チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
|
CN112867512A
(zh)
|
2018-09-25 |
2021-05-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
JP2022502385A
(ja)
|
2018-09-29 |
2022-01-11 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物の製造方法
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
AU2020263959A1
(en)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
BR112022002518A2
(pt)
|
2019-08-15 |
2022-07-19 |
Black Diamond Therapeutics Inc |
Compostos de alquinila quinazolina
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
WO2022043256A1
(en)
|
2020-08-23 |
2022-03-03 |
Cobiores Nv |
Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
JP2023554520A
(ja)
|
2020-12-22 |
2023-12-27 |
コビオレス エヌヴイ |
テトラペプチド部分を含む化合物
|
AU2021409561A1
(en)
|
2020-12-22 |
2023-07-06 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
EP4277901A1
(de)
|
2021-01-13 |
2023-11-22 |
Monte Rosa Therapeutics, Inc. |
Isoindolinonverbindungen
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
WO2022167664A1
(en)
|
2021-02-07 |
2022-08-11 |
Cobiores Nv |
Compounds comprising a tetrapeptidic moiety
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
EP4323349A1
(de)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinonamidverbindungen zur behandlung von krankheiten im zusammenhang mit gspt1
|
EP4323350A1
(de)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinonverbindungen
|
TW202317589A
(zh)
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為kras抑制劑的伸烷基衍生物
|
US20230303509A1
(en)
|
2022-03-28 |
2023-09-28 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|